Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

R9 > Chapter 137 - Vasculitis and other uncommon arteriopathies > Flashcards

Chapter 137 - Vasculitis and other uncommon arteriopathies Flashcards

1
Q

International Chapel Hill Consensus Conference Nomenclature

A

TABLE 137.1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Large vessel vasculitis examples

A

1) GCA (temporal) 2) Takayasu

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Medium vessel vasculitis examples

A

1) Polyarteritis nodosa 2) Kawasaki disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Small vessel vasculitis categories

A

1) Immune complex-mediated 2) antineutrophil cytoplasmic antibody mediated (ANCA-associated pauci-immune)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Immune complex-mediated small vessel vasculitis examples

A

1) Antiglomerular basement membrane disease (anti-GBM) 2) Cryoglobulinemic vasculitis 3) IgA vasculitis (Henoch-Schonlein purpura) 4) Hypocomplementemic urticarial vasculitis (anti-C1q vasculitis)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Antineutrophil cytoplasmic antibody-mediated (ANCA-associated pauci-immune) small vessel vasculitis examples

A

1) Granulomatosis with polyangiitis (Wegener’s) 2) Microscopic polyangiitis 3) Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Variable-vessel vasculitis examples

A

1) Behcet 2) Cogan 3) Thromboangiitis obliterans (Buerger’s)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Single-organ vasculitis examples

A

1) Cutaneous leukocytoclastic vasculitis 2) Cutaneous arteritis 3) Primary CNS vasculitis (isolated angiitis of CNS) 4) isolated aortitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Vasculitis associated with systemic disease examples

A

1) Lupus vasculitis 2) Rheumatoid vasculitis 3) Sarcoid vasculitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Vasculitis secondary to other etiology examples

A

1) Hepatitis C-associated cryoglobulinemic vasculitis 2) Hepatitis B associated vasculitis 3) Syphilis-associated vasculitis 4) Drug-associated immune complex vasculitis (hypersensitivity vasculitis) 5) cancer-associated vasculitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Typical presentation of large vessel vasculitis

A

1) limb claudication 2) vascular bruits 3) asymmetric blood pressure 4) absent pulses

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Typical presentation of medium vessel vasculitis

A

1) cutaneous nodules and ulcers 2) livedo reticularis 3) digital gangrene 4) mononeuritis multiplex 5) renovascular hypertension

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Typical presentation of small vessel vasculitis

A

1) palpable purpura 2) pulmonary-renal syndrome (glomerular nephritis, alveolar hemorrhage) 3) urticarial skin rash 4) scleritis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Histological findings of vasculitis

A

1) infiltration of vessel wall by neutrophil, mononuclear cells, giant cells 2) fibrinoid necrosis with pan-mural descruction 3) nuclear dust - from destruction of leukocytes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Angiographic finding of vasculitis

A

1) beading 2) irregular asymmetrical tapering 3) segmental stenosis 4) aneurysm formation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

MRI and PET scans in vasculitis

A

1) Gadolinium in aortic wall indicate active inflammation 2) PET demonstrate enhancement in large vessel vasculitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Giant cell arteritis epidemiology

A

1) Over 50 years of age 2) elderly more affected (80’s have 10x higher risk than 50’s) 3) 2:1 female:male

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Cause of GCA

A

unknown but have theories 1) HLA-DRB1*04 and DRB1*01 2) T-cell cytokine IFN-gamma expression injury –> growth and angiogenic factors –> proliferation of myofibroblast –> new vessel formation –> thickening of arterial intima –> vessel occlusion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Symptoms of GCA

A

1) cranial symptoms: HA, scalp tender, jaw and tongue claudication, diplopia, blindness 20% 2) polymyalgia rheumatica 40% 3) fever and systemic symptoms without localizing symptoms 15% 4) claudication, cough, tenosynovitis 5%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Percentage of patients with polymyalgia rheumatica that develop GCA

A

10-20%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Percentage of elderly patients with fever of unknown origin that ends up being GCA

A

15%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Increased risk in GCA of developing thoracic and abdominal aneurysms

A

17x TAAA 2.4x AAA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Relative risk of blindness in GCA after amaurosis fugax

A

6.3x

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Cause of abrupt onset of painless blindness in GCA

A

arteritis of posterior ciliary branches of the ophthalmic arteries

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Risk of blindness in GCA after steroids have been initiated

A

10%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Thrombocytosis of ophthalmic artery in GCA symptoms

A

1) iritis 2) conjunctivitis 3) scintillating scotoma 4) photophobia 5) glaucoma 6) opthalmoplegia (ischemia of extraocular muscles)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Diagnostic criteria of GCA

A

1990 American college of rheumatology 3/5 present = sensitivity 93.5 specificity 91.2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Principles of temporal artery biopsy

A

1) 2-3 cm 2) bilateral biopsy can be done 3) 50% show diffuse lymphocytic infiltration without granulomatous inflammation or GC 4) fragmentation and fraying of internal elastic lamina is normal aging 5) done within 7 days of steroids

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Steroid treatment in GCA

A

1) initial dose 40-60 mg daily 2) if blindness then IV methylprednisolone 1g/day x 3 days 3) prednisone maintained until inflammatory markers normalize (takes > 1 month)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Prednisone tapering

A

1) reduce 5mg every 1-2 weeks until 30 mg/day 2) reduce 2.5 mg every 1-2 weeks until 15 mg/day 3) reduce 2.5 mg every 4 weeks until 10 mg/day 4) reduce 1 mg every 4 weeks until patient is off

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Rate of spontaneous recurrence in GCA

A

50%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

Other drugs used in GCA

A

1) ASA 2) anti-IL6 antibody Tocilizumab 3) biologic and non-biologic disease modifying antirheumatic drugs (DMARDS)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Ormond disease; what is it, epidemiology

A

1) Idiopathic retroperitoneal fibrosis 2) male:female 3:1 3) middle age 40-60

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

Symptoms of Ormond disease

A

1) systemic symptoms 2) HTN 75% 3) LE edema and phlebitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

Diagnosis Ormond - lab

A

serology negative, inflammatory marker elevated in 75%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

Diagnosis Ormond - CT finding

A

1) Homogenous mass around aorta and iliac bifurcation 2) medial deviation of mid-part of ureter 3) secondary hydronephrosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

Treatment of Ormond

A

Prednisone 1-3 years Others: mycophenolate mofetil, tamoxifen, methotrexate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

Disease recurrence in Ormond

A

10-30%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

IgG4 related systemic disease epidemiology

A

Men > 50 years of age In people with history of allergic disease and atopy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

Diagnosis of IgG4-related disease

A

1) tumor-like lesions with dense lymphoplasmacytic infiltrates with storiform fibrosis and obliterative phlebitis 2) lesions with IgG4/IgG positive ratio > 50% 3) elevated serum IgG4 60-80% 4) negative serology

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

IgG4-related disease specific types

A

1) Type 1 autoimmune pancreatitis 2) sclerosing cholangitis 3) salivary gland involvement (Mikulicz disease) 4) sclerosing sialadenitis (Kuttner tumor)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

Treatment of IgG4

A

steroids with DMARDS Rituximab (B cell target)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

Erdheim-Chester disease define

A

Rare histiocytic disease with 1) periaortic fibrosis 2) periarterial infiltration of coronary arteries 3) pericardial thickening and effusion 4) Hairy kidney 5) retroperitoneal mass like infiltrative lesion 6) bone lesions (juxtaarticular pain) - KEY FEATURE that differentiates it from others

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

Cause of Erdheim-Chester disease

A

Gain of function mutation in proto-oncogene BRAF BRAFV600E

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

Polyarteritis nodosa (PAN) define

A

Necrotizing vasculitis of small and medium arteries absence of glomerulonephritis and ANCA antibodies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

Diagnosis of PAN

A

3/10 have to be present

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

Causes of PAN

A

1) idiopathic 2) Hep B associated (mean time 7 months) 3) other viral infections (HIV) 4) paraneoplastic manifestation (hairy cell leukemia)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

Histology of PAN

A

1) focal segmental necrotizing vasculitis 2) medium sized arteries 3) fibrinoid necrosis of media 4) neutrophilic and lymphocytic infiltrate 5) active necrotizing lesions alongside healed fibrotic lesions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

Lab testing for PAN

A

no specific serologic test available

50
Q

PAN symptoms

A

1) constitutional symptoms 2) organ dysfunction 3) skin: palpable purpura, livedo, necrotic lesions, digital infarcts 4) peripheral neuropathy and mononeuritis multiplex 5) abd pain from mesenteric vasculitis 6) HTN 7) microscopic hematuria and proteinuria 8) skeletal muscle myalgia

51
Q

Renal biopsy in PAN

A

not helpful since no glomerular involvement

52
Q

Key difference between PAN and ANCA-associated vasculitides

A

PAN does not affect lungs or upper respiratory tract

53
Q

Treatment for PAN

A

1) antiviral first if infection 2) steroids 3) DMARDS 4) cyclophosphamide

54
Q

Methotrexate cannot be used in which patients

A

Renal disease or hepatitis

55
Q

Cyclophosphamide side effect

A

1) cytopenia 2) gonadal failure 3) hemorrhagic cystitis 4) malignancy

56
Q

Patients with high dose steroid and DMARDS need prophylaxis against this

A

pneumocystis jirovecii (PJP)

57
Q

Survival of PAN without treatment and with treatment

A

13% without treatment 80% with treatment 5 year

58
Q

Factors associated with poor survival in PAN

A

1) Age > 65 2) cardiac symptoms 3) GI involvement 4) renal insufficiency Cr > 170

59
Q

PAN recurrence in transplanted kidney

A

13%

60
Q

Segmental arterial mediolysis (SAM) key points

A

1) rare 2) nonatherosclerotic, noninflammatory disease 3) affect muscular arteries and mimic PAN 4) variant of fibromuscular dysplasia

61
Q

Segmental arterial mediolysis affects different parts at different ages

A

Aorta is spared Elderly - splanchnic arteries Adults - basilar cerebral Young - coronary

62
Q

Other disease that mimic PAN

A

1) SAM 2) pseudoxanthoma elasticum 3) neurofibromatosis 4) vascular type Ehlers Danlos 5) adenosine deaminase-2 deficiency

63
Q

Thromboangiitis obliterans define and epidemiology

A

1) Buerger’s disease 2) Age 18-50 3) men > woman 4) middle east and far east 5) related to smoking

64
Q

Diagnosis of thromboangiitis obliterans

A

1) diagnosis of exclusion 2) rule out scleroderma first 3) echo and arteriogram

65
Q

Arteriography features of TO

A

1) bilateral focal segmental stenosis/occlusion with relatively normal intervening vessels 2) tree-root/spiderweb/corkscrew collaterals 3) normal proximal artery

66
Q

Pathologic findings of TO

A

1) cellular thrombosis and microabscesses 2) panvasculitis 3) internal elastic lamina preserved (KEY FATURE) 4) vein sparing

67
Q

treatment of TO

A

1) stop smoking 2) calcium channel blocker 3) pentoxifylline 4) iv iloprost 5) sympathectomy

68
Q

Risk of amputation in smokers that continue to smoke in TO

A

50%

69
Q

Kawasaki disease definition and key points

A

1) children (most < 5 years) 2) small and medium sized (coronary most common) 3) coronary dilatation/aneurysm 20-29% 4) female 1.5: male 1 5) high grade fever 6) death by MI

70
Q

Treatment of Kawasaki

A

1) high dose aspirin 2) IVIG

71
Q

ANCA define

A

Antibiotics directed against specific proteins in granules in the cytoplasm of neutrophils and lysosomal proteins in monocytes

72
Q

ANCA vasculitis classes

A

GPA: granulomatosis with polyangiitis (Wegener) MPA: microscopic polyangiitis EGPA: eosinophilic granulomatosis with polyangiitis (Churg-Strauss)

73
Q

GPA epidemiology

A

1) mean age 41 2) 16% present in childhood 3) caucasian 7:1 black

74
Q

GPA subclassification

A

Generalized GPA: upper and lower respiratory tract and kidney Limited GPA: resp track only

75
Q

GPA symptoms

A

pulmonary involvement 50% at presentation, 90% eventual enal involvement 15-30% at presentation, 50-80% eventual 1) chronic sinusitis 2) epistaxis 3) chronic purulent nasal drainage 4) chronic inflammation of auditory canal (suppurative and chronic serous otitis media 5) laryngeal and tracheal inflammation (hoarseness, subglottic stenosis) 6) mononeuritis multiplex 7) chronic pachymenigitis, cranial neuropathies, pituitary involvement, brainstem and spinal cord lesions

76
Q

Pulmonary involvement of GPA

A

1) nodules and infiltrates 2) granuloma in alveolar septa

77
Q

ANCA level in GPA

A

1) ANCA positive in 90% with generalized GPA and 60% limited GPA 2) 80-90% have cANCA positive with PR3 specificity 3) correlate with GPA flare if highly elevated

78
Q

Specificity of PR3-ANCA for GPA

A

98%

79
Q

Treatment for GPA

A

1) IV methylprednisolone 1g/day 2) rituximab and cyclophosphamide 3) plasmaphoresis milder 4) prednisone 5) methotrexate

80
Q

Maintenance phase of GPA treatment

A

Azathioprine has less side effect than cytoxan

81
Q

Relapse of GPA

A

50%

82
Q

Microscopic polyangiitis (MPA) define

A

1) systemic necrotizing vasculitis of small vessels 2) ANCA formation 3) no immune deposits on histology (pauci-immune) 4) no granuloma formation

83
Q

MPA epidemiology

A

1) men = women 2) age 30-50

84
Q

Lab finding of MPA

A

pANCA in 60% can still have cANCA with specificity against PR3

85
Q

How to differentiate MPA from GPA

A

MPA does not have upper resp involvement

86
Q

Histopathology of MPA

A

1) segmental necrotizing glomerulonephritis with crescent formation 2) pulmonary capillaritis with negative immunofluorescence 3) skin = leukocytoclastic vasculitis

87
Q

Treatment of MPA

A

1) IV steroid 2) oral prednisone 3) cyclophosphamide or rituximab 4) IVIG and plasmaphoresis (if acute pulmonary hemorrhage

88
Q

Relapse of MPA

A

33% 20% need dialysis

89
Q

5 year survival of MPA

A

70-75%

90
Q

Eosinophilic granulomatosis with polyangiitis define

A

1) Churg-Strauss Syndrome 2) granulomatous vasculitis of small and medium-sized vessel with eosinophilia 3) history of allergic disease with rhinitis 70% or adult-onset asthma 95%

91
Q

Diagnostic criteria of EGPA

A

4/6 sen 85% spe 99.7% 1) asthma 2) eosinophilia > 10% 3) mono or poly-neuropathy 4) nonfixed pulmonary infiltrates 5) paranasal sinus abnormalities 6) biopsy with eosinophilic infiltrates

92
Q

Pathophysiology of EGPA

A

1) cytokine pathway IL5 stimulate eosinophil 2) leukotriene inhibitor contribute to pathogenesis 3) extravascular necrotizing granuloma near small artery and vein

93
Q

Difference of EGPA from other granulomatous lesions

A

Eosinophilic core rather than basophilic core radially surrounded by macrophages and giant cells

94
Q

Triphasic process of EGPA

A

1) Prodromal phase (28 months up to 7 years) - allergic rhinitis, asthma, nasal polyposis - 50% recurrent fever 2) Eosinophilia - shifting pulmonary infiltrates - chronic eosinophilic pneumonia - eosinophilic gastroenteritis 3) systemic vasculitis (3 years after onset) - myocarditis, valvular insufficiency - vasculitic peripheral neuropathy - eosinophilic gastroenteritis, purpura and testicular pain

95
Q

Lab finding in EGPA

A

Eosinophilia > 1500 cells/mcL pANCA with anti MPO specificity positive RF

96
Q

Treatment of EPGA

A

1) IV glucocorticoids 2) oral prednisone 3) cyclophosphamide 4) rituximab

97
Q

Behçet disease define

A

systemic vasculitis of unknown etiology Vascular complication with high venous thrombosis rate and 1-7% arterial thrombosis 1) genital ulcers 2) uveitis 3) skin lesions 4) vascular manifestations

98
Q

Venous thrombosis in Behcet disease

A

1) superficial and deep vein thrombosis 2) thrombosis of large central vein including SVC and IVC 3) Hepatic vein thrombosis = Budd Chiari syndrome 4) intracranial thrombosis in dural sinus

99
Q

Unique feature of venous thrombosis in Behcet disease

A

clot adherent to vessel wall thrombosis can progress despite anticoagulation

100
Q

Arterial aneurysm formation in Behcet disease order of frequency and vessel type

A

Aorta > pulmonary > femoral> popliteal > brachial > iliac

101
Q

Epidemiology of Behcet disease

A

1) Turkey and Mediterranean basin, Middle and Far East along the historic silk road trade route 2) age 20-40 3) genetic, infectious and immunologic factors 4) HLA-B51 genotype

102
Q

Treatment of Behcet

A

1) glucocorticoid 2) steroid-sparing DMARD agents 3) colchicine for mucocutaneous lesions 4) Thalidomide for genital and oral ulcers 5) high dose steroids and cytotoxic agents for vasculitis

103
Q

SLE define

A

Chronic multisystem autoimmune disease with autoantibody to various nuclear antigens

104
Q

Rate of SLE with vasculitis

A

1/3 of SLE patients

105
Q

Most commonly affected vessel in SLE vasculitis

A

Small vessel of skin Leukocytoclastic vasculitis

106
Q

Treatment of vasculitis in SLE

A

Steroids and DMARDS Anticoagulation and Hydroxychloroquine if antiphospholipid antibodies present

107
Q

Rheumatoid vasculitis rate

A

10-15% of RA

108
Q

Relapsing polychondritis define

A

Rare autoimmune disease with recurrent inflammation of cartilaginous tissue Can lead to large vessel aortitis and aneurysms

109
Q

Cogan’s syndrome define

A

Large and medium vasculitis (like Takayasu) Immune-mediated characterized by: 1) interstitial keratitis 2) vestibular dysfunction 3) sensorineural hearing loss

110
Q

Epidemiology of Cogan’s syndrome

A

mean age 30’s Equal men and women No racial predilection Ear and eye involvement develop within 6 months of each other

111
Q

Interstitial keratitis manifestations

A

1) redness 2) pain 3) photophobia 4) increase lacrimation

112
Q

Vestibular dysfunction manifestation

A

1) tinnitis 2) vertigo 3) sensorineural hearing loss deaf in 50% of Cogan’s syndrome

113
Q

Pseudoxanthoma elasticum define

A

1) inherited systemic disease causing early and diffuse arteriopathy 2) small and medium vasculitis

114
Q

Pseudoxanthoma elasticum symptoms

A

1) claudication 2) coronary artery 3) internal mammary 4) GI and GU rupture

115
Q

Exercise-related external iliac arteriopathy define

A

1) competitive cyclists with 8000-33000 km/year 2) men + women 3) external iliac artery 4) repetitive bending

116
Q

Exercise-related EIA arteriopathy mechanism

A

Psoas branch, circumflex iliac and internal iliac cause fibrosis and thickening of EIA SMC migration and intimal thickening

117
Q

Treatment of endofibrosis in EIA

A

1) bypass 2) endarterectomy 3) POBA 4) stenting

118
Q

Radiation arteritis mechanism

A

1) endothelial damage, intimal thickening, smooth muscle loss with fibrosis 2) calcification and typical atherosclerosis 3) bulky stenosis 4) medial necrosis 5) vasa vasorum obliteration with adventitial scarring

119
Q

Neurofibromatosis Type 1 key points

A

1) autosomal dominant disorder 2) loss of function mutation of tumor suppressor NF-1 3) affects 1:3000 4) neurofibroma, schwannoma, pheochromocytoma 5) 0.4-6.4% get vascular manifestation

120
Q

NF1 vascular manifestations

A

1) saccular/fusiform aneurysms 2) stenotic lesions 3) AVM 4) extrinsic compression from neurofibromas

121
Q

Drug induced (hypersensitivity) vasculitis caused by

A

1) chemotherapeutic agents 2) growth factors 3) interferons 4) antithyroid drugs 5) hydrochlorthiazide 6) hydralazine 7) minocycline 8) penicillamine 9) vaccine 10) beta blocker - mild vasospasm and exacerbate Raynauds 11) Ergot - vasospasm 12 Cocaine

122
Q

Cocaine with levamisole vasculitis

A

1) skin necrosis (nose, ears, breast, digits 2) tissue loss 3) palpable purpura into cookie cutter edge 4) multicentric and doesn’t conform to vascular territory 5) painful worse with elevation

R9 (200 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions